Recent pre-clinical studies have also explored interferon β (IFNβ) as a potential anti-fibrotic for NASH, with its ability to downregulate fibrogenic genes associated with TGFβ-1 and MyD88 pathways [15]. The gene discussed is MYD88; the disease is metabolic dysfunction-associated steatohepatitis.